Compare Ascendis Pharma A/S (ASND) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Vanguard Dividend Appreciation Index Fund ETF trades at $238.95. Which is the better fit depends on your goals.
| ASND | VIG | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $239.03 |
52-Week Low | $163.32 | $204.09 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
VIG trades at $238.84, up 0.09% with a bullish technical outlook from moving averages and a neutral oscillator stance. The ETF focuses on U.S. dividend growth stocks, offering a low 0.04% expense ratio and a recent dividend of $1.00 payable June 30, 2026. News highlights its role in defensive strategies amid market volatility, with comparisons to peers like SCHD and DGRO emphasizing its growth-oriented approach.
The outlook remains positive due to strong technical momentum and dividend stability, but risks include market sensitivity to interest rates and competition from higher-yield alternatives. Analyst sentiment is mixed, with some favoring VIG for long-term wealth building while others note underperformance versus rivals in yield-focused segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
